CA2540076A1 - Ophthalmic device comprising a holographic sensor - Google Patents
Ophthalmic device comprising a holographic sensor Download PDFInfo
- Publication number
- CA2540076A1 CA2540076A1 CA002540076A CA2540076A CA2540076A1 CA 2540076 A1 CA2540076 A1 CA 2540076A1 CA 002540076 A CA002540076 A CA 002540076A CA 2540076 A CA2540076 A CA 2540076A CA 2540076 A1 CA2540076 A1 CA 2540076A1
- Authority
- CA
- Canada
- Prior art keywords
- medium
- glucose
- holographic
- acid
- analyte
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 56
- 239000008103 glucose Substances 0.000 claims abstract description 56
- 239000012491 analyte Substances 0.000 claims abstract description 21
- 230000003287 optical effect Effects 0.000 claims abstract description 15
- 230000003993 interaction Effects 0.000 claims abstract description 12
- 239000012530 fluid Substances 0.000 claims abstract description 11
- 230000000704 physical effect Effects 0.000 claims abstract description 10
- 238000001514 detection method Methods 0.000 claims abstract description 9
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 18
- 230000008859 change Effects 0.000 claims description 14
- 239000000178 monomer Substances 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 8
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical group OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 claims description 8
- 125000005620 boronic acid group Chemical group 0.000 claims description 7
- 238000004132 cross linking Methods 0.000 claims description 7
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 claims description 6
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical group [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 claims description 6
- 229910052796 boron Inorganic materials 0.000 claims description 6
- 230000002441 reversible effect Effects 0.000 claims description 6
- 238000006243 chemical reaction Methods 0.000 claims description 5
- NEYTXADIGVEHQD-UHFFFAOYSA-N 2-hydroxy-2-(prop-2-enoylamino)acetic acid Chemical compound OC(=O)C(O)NC(=O)C=C NEYTXADIGVEHQD-UHFFFAOYSA-N 0.000 claims description 4
- ULVXDHIJOKEBMW-UHFFFAOYSA-N [3-(prop-2-enoylamino)phenyl]boronic acid Chemical compound OB(O)C1=CC=CC(NC(=O)C=C)=C1 ULVXDHIJOKEBMW-UHFFFAOYSA-N 0.000 claims description 4
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims description 4
- VNVCFMWOHSTLRQ-UHFFFAOYSA-N [5-fluoro-2-(2-methylprop-2-enoylamino)phenyl]boronic acid Chemical compound CC(=C)C(=O)NC1=CC=C(F)C=C1B(O)O VNVCFMWOHSTLRQ-UHFFFAOYSA-N 0.000 claims description 3
- 125000003277 amino group Chemical group 0.000 claims description 3
- 229910052709 silver Inorganic materials 0.000 claims description 3
- 239000004332 silver Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000001846 repelling effect Effects 0.000 claims 1
- 239000002609 medium Substances 0.000 description 44
- 230000004044 response Effects 0.000 description 12
- 239000000463 material Substances 0.000 description 11
- 239000004372 Polyvinyl alcohol Substances 0.000 description 10
- 229920002451 polyvinyl alcohol Polymers 0.000 description 10
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 10
- 239000011159 matrix material Substances 0.000 description 9
- 108020003175 receptors Proteins 0.000 description 9
- 102000005962 receptors Human genes 0.000 description 9
- -1 vinyl lactam Chemical class 0.000 description 9
- 239000000017 hydrogel Substances 0.000 description 8
- 230000027455 binding Effects 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000007943 implant Substances 0.000 description 6
- 241000894007 species Species 0.000 description 6
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 5
- 108090001090 Lectins Proteins 0.000 description 5
- 102000004856 Lectins Human genes 0.000 description 5
- 239000002523 lectin Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 229920002635 polyurethane Polymers 0.000 description 4
- 239000004814 polyurethane Substances 0.000 description 4
- 230000005855 radiation Effects 0.000 description 4
- KUQRLZZWFINMDP-BGNLRFAXSA-N 2-[(3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyethyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCCOC1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O KUQRLZZWFINMDP-BGNLRFAXSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 108010062580 Concanavalin A Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000036765 blood level Effects 0.000 description 3
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical class OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 150000003983 crown ethers Chemical group 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 229920002554 vinyl polymer Polymers 0.000 description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 208000010412 Glaucoma Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 229920002396 Polyurea Polymers 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 229920001515 polyalkylene glycol Polymers 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 229920002818 (Hydroxyethyl)methacrylate Polymers 0.000 description 1
- KVZLHPXEUGJPAH-UHFFFAOYSA-N 2-oxidanylpropanoic acid Chemical compound CC(O)C(O)=O.CC(O)C(O)=O KVZLHPXEUGJPAH-UHFFFAOYSA-N 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 102100026735 Coagulation factor VIII Human genes 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- PHOQVHQSTUBQQK-SQOUGZDYSA-N D-glucono-1,5-lactone Chemical compound OC[C@H]1OC(=O)[C@H](O)[C@@H](O)[C@@H]1O PHOQVHQSTUBQQK-SQOUGZDYSA-N 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- 108010065556 Drug Receptors Proteins 0.000 description 1
- 102000013138 Drug Receptors Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- IMROMDMJAWUWLK-UHFFFAOYSA-N Ethenol Chemical compound OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- OLBVUFHMDRJKTK-UHFFFAOYSA-N [N].[O] Chemical compound [N].[O] OLBVUFHMDRJKTK-UHFFFAOYSA-N 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000001742 aqueous humor Anatomy 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 150000001642 boronic acid derivatives Chemical class 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 1
- 150000002009 diols Chemical group 0.000 description 1
- 210000003717 douglas' pouch Anatomy 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000005670 electromagnetic radiation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 235000012209 glucono delta-lactone Nutrition 0.000 description 1
- 229960003681 gluconolactone Drugs 0.000 description 1
- 108010070004 glucose receptor Proteins 0.000 description 1
- 108091008039 hormone receptors Proteins 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- IQPQWNKOIGAROB-UHFFFAOYSA-N isocyanate group Chemical group [N-]=C=O IQPQWNKOIGAROB-UHFFFAOYSA-N 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- ZIUHHBKFKCYYJD-UHFFFAOYSA-N n,n'-methylenebisacrylamide Chemical compound C=CC(=O)NCNC(=O)C=C ZIUHHBKFKCYYJD-UHFFFAOYSA-N 0.000 description 1
- ADTJPOBHAXXXFS-UHFFFAOYSA-N n-[3-(dimethylamino)propyl]prop-2-enamide Chemical compound CN(C)CCCNC(=O)C=C ADTJPOBHAXXXFS-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 229920000083 poly(allylamine) Polymers 0.000 description 1
- 229920001281 polyalkylene Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
- 229920006254 polymer film Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 125000002924 primary amino group Chemical class [H]N([H])* 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 125000000467 secondary amino group Chemical class [H]N([*:1])[*:2] 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 229920006301 statistical copolymer Polymers 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 125000002348 vinylic group Chemical group 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
Classifications
-
- G—PHYSICS
- G02—OPTICS
- G02B—OPTICAL ELEMENTS, SYSTEMS OR APPARATUS
- G02B1/00—Optical elements characterised by the material of which they are made; Optical coatings for optical elements
- G02B1/04—Optical elements characterised by the material of which they are made; Optical coatings for optical elements made of organic materials, e.g. plastics
- G02B1/041—Lenses
- G02B1/043—Contact lenses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
- G01N21/77—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator
-
- G—PHYSICS
- G02—OPTICS
- G02C—SPECTACLES; SUNGLASSES OR GOGGLES INSOFAR AS THEY HAVE THE SAME FEATURES AS SPECTACLES; CONTACT LENSES
- G02C7/00—Optical parts
- G02C7/02—Lenses; Lens systems ; Methods of designing lenses
- G02C7/04—Contact lenses for the eyes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
- G01N2021/758—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated using reversible reaction
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
- G01N21/77—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator
- G01N21/7703—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator using reagent-clad optical fibres or optical waveguides
- G01N2021/7706—Reagent provision
- G01N2021/7723—Swelling part, also for adsorption sensor, i.e. without chemical reaction
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
- G01N21/77—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator
- G01N2021/7769—Measurement method of reaction-produced change in sensor
- G01N2021/7773—Reflection
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
- G01N21/77—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator
- G01N21/78—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator producing a change of colour
Landscapes
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Plasma & Fusion (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Optics & Photonics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Eyeglasses (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Diffracting Gratings Or Hologram Optical Elements (AREA)
- Prostheses (AREA)
Abstract
An ophthalmic device comprises a holographic element comprising a medium and, disposed therein, a hologram, wherein an optical characteristic of the element changes as a result of a variation of a physical property of the medium, and wherein the variation arises as a result of interaction between the medium and an analyte present in an ocular fluid. The device may be used for the detection of analytes such as glucose.
Description
OPHTHALMIC DEVICE COMPRISING A HOLOGRAPHIC SENSOR
Field of the Invention This invention relates to an ophthalmic device comprising a holographic sensor.
Background to the Invention Ophthalmic devices, for example contact lenses, comprising holographic elements are known. Typically, a holographic element is used to focus incoming light. The holographic element may have a programmed activating angle providing two or more optical powers. The use of a holographic element allows the user to see clear and unimpaired images, thereby overcoming many of the shortfalls of traditional simultaneous vision and translating lenses.
Holographic optical inserts are described, for example, in WO-A-99/34239, WO-A-99/34244, WO-A-02/054137 and WO-A-99/34248.
The need for minimally invasive, easy-to-use glucose sensors has motivated the investigation of numerous approaches. One particular area of interest is ophthalmic glucose sensors, i.e. those for the detection of glucose in the eye. The levels of glucose in the eye are known to correlate with those in the blood, and thus blood levels of glucose can be monitored indirectly by measuring the levels in an ocular fluid such as tears.
US-A-200310027240 describes an ocular insert for the detection of glucose. The insert comprises a polymerised crystalline colloidal array (PCCA) which is polymerised in a hydrogel, and a molecular recognition component capable of responding to glucose. The array has a lattice spacing that changes when the volume of the hydrogel changes, causing the diffracted wavelength of the array to change.
WO-A-95/26499 discloses a holographic sensor, based on a volume hologram. This sensor comprises an analyte-sensitive matrix having an optical transducing structure disposed throughout its volume. Because of this physical arrangement of the transducer, the optical signal generated by the sensor is very sensitive to volume changes or structural rearrangements taking place in the analyte-sensitive matrix as a result of interaction or reaction with the analyte.
For example, a sensor comprising a gelatin-based holographic medium may be used to detect trypsin. Trypsin acts on the gelatin medium, irreversibly destroying the integrity of the holographic support medium. Holographic sensors may also be used to detect changes in, for example, pH.
Although sensors of the kind described in US-A-2003/0027240 may be used to detect levels of glucose in the eye, there remains the need for ophthalmic sensors which allowfor accurate, real-tim a detection of analytes such as glucose.
Summary of the Invention The present invention is based on the realisati on that holographic sensing technology, when incorporated into a contact lens or other ophthalmic device, provides an accurate yet minimally invasive method of detection of an ocular analyte. Such sensing technology may allow for the continuous, real-time sensing of glucose or other carbohydrates. The invention thus may improve the lives of patients having diabetes and decrease such patients' risk of developing hypoglycemia or hyperglycemia.
Afirst aspect of the invention is an ophthalmic device which comprises a holographic element comprising a medium and, dis posed therein, a hologram, wherein an optical characteristic of the element changes as a result of a variation of a physical property of the medium, and wherein the variation arises as a result of interaction between the medium and an analyte present in an ocular fluid. The device may be a contact lens or an ocular implant.
Another aspect of the invention is a method of detection of an analyte in an ocular fluid, the method comprising detecting any change of the optical characteristic of the holographic element of a device of the invention with the fluid, in the eye.
Another aspect of the invention is a method for the production of a device of the invention which comprises contacting the holographic element with a contact lens, wherein the contacted regions of the element and the lens are cross-linkable; and cross-linking said regions. Preferably, at least one of the contacted regions comprises PVA, more preferably Nelfilcon.
The invention may be used for the detection of ocular analytes such as glucose or lactate. The interaction is preferably reversible so that both the interaction and reverse interaction can occur, allowing the analyte to be continuously detected, preferably in real time. The interaction is preferably a chemical reaction.
Description of the Invention The term "glucose" as used herein refers to the known cyclic and linear forms of glucose.
w The term "ophthalmic device" as used herein refers to contact lenses (both hard and soft), corneal onlays, implantable ophthalmic devices and the like.
The term "contact lens" as used herein refers to any hard or soft lens used on the eye or ocular vicinity for vision correction, diagnosis, sample collection, drug delivery, wound healing, cosmetic appearance or other ophthalmic application. The lens may be a daily-disposable, daily-wear or extended-wear lens.
The term "implantable ophthalmic device" as used herein refers to an ophthalmic device which is used in, on or about the eye or ocular vicinity.
Such devices include intraocular lenses, subconjunctival lenses, intracorneal lenses, and shunts/implants (e.g. a stent or glaucoma shunt) that can rest in the cul de sac of an eye.
In a preferred embodiment, the insert is in the form of a contact lens. The lens may be manufactured using any suitable material known in the art. The lens material may be formed by the polymerisation of one or more monomers and optionally one or more prepolymers. The material may comprise a photoinitiator, visibility tinting agent, UV-blocking agent and/or a photosensitiser.
A preferred group of lens materials are prepolymers which are water-soluble and/or meltable. It is preferred that the material comprises one or more prepolymers which are in a substantially pure form (e.g. purified by ultrafiltration). Preferred prepolymers include water-soluble crosslinkable polyvinyl alcohol) prepolymers (as described in US5583163 and US6303687);
a water-soluble vinyl group-terminated polyurethane, obtainable by reacting an isocyanate-capped polyurethane with an ethylenically unsaturated amine (primary or secondary amine) or an ethylenically unsaturated monohydroxy compound, wherein the isocyanate-capped polyurethane can be a copolymerisation product of at least one polyalkylene glycol, a compound containing at least 2 hydroxyl groups, and at least one compound with two or more isocyanate groups; derivatives of a polyvinyl alcohol, polyethyleneimine or polyvinylamine (see, for example, US5849841); a water-soluble crosslinkable polyurea prepolymer as described in US6479587; crosslinkable polyacrylamide;
crosslinkable statistical copolymers of vinyl lactam, MMA and a comonomer, as disclosed in EP-A-0655470 and US5712356; crosslinkable copolymers of vinyl lactam, vinyl acetate and vinyl alcohol, as disclosed in EP-A-0712867 and US5665840; polyether-polyester copolymers with crosslinkable side chains, as disclosed in EP-A-0932635; branched polyalkylene glycol-urethane prepolymers, as disclosed in EP-A-0958315 and US6165408; polyalkylene glycol tetra(meth)acrylate prepolymers, as disclosed in EP-A-0961941 and US6221303; and crosslinkable polyallylamine gluconolactone prepolymers, as disclosed in WO-A-00/31150.
The lens may comprise a hydrogel material. Typically, hydrogel materials are polymeric materials which are capable of absorbing at least 10% by weight of water when fully hydrated. Hydrogel materials include polyvinyl alcohol) (PVA), modified PVA (e.g. nelfilcon A), poly(hydroxyethyl methacrylate), polyvinyl pyrrolidone), PVA with a poly(carboxylic acid) (e.g. carbopol), polyethylene glycol), polyacrylamide, polymethacrylamide, silicone-containing hydrogels, polyurethane, polyurea, and the like.
Alternatively, the device may be an implantable ophthalmic device.
Glucose levels in tears may be much lower than blood glucose levels. With an implantable ophthalmic sensor, one can monitor glucose levels in aqueous humor or interstitial fluid, where glucose levels can be much higher than glucose levels in tears. Preferably, the device is in the form of a subconjunctive implant, intracorneal lens, stent or glaucoma shunt.
The holographic support medium is one in which a hologram can be made and which is capable of exhibiting one or more of the properties of the sensitive mechanisms described herein. The hologram may be disposed on or in, part of or throughout the bulk of the volume of the support medium. Particularly in the case of a contact lens, the support medium may be an integral part of the device, e.g. the body of a lens may itself comprise or form a holographic support medium.
The support medium preferably comprises a native or modified matrix with 5 viscoelastic properties which alter as a result of an interaction with an analyte species. For example, the matrix may be formed from the copolymerisation of (meth)acrylamide and/or (meth)acrylate-derived comonomers. In particular, the monomer HEMA (hydroxyethyl methacrylate) is readily polymerisable and cross-linkable. PoIyHEMA is a versatile support material since it is swellable, hydrophilic and widely biocompatible.
A device in the form of a contact lens is preferably obtained by forming a holographic element and then embedding the element into a contact lens. For example, a contact lens sensor may be obtained using the following protocol:
(a) forming a polymeric holographic sensor(e.g. using phenylboronate ligands) on a glass slide or similar surface;
(b) coating a layer of polyvinylalcohol (PVA), preferably "Nelfilcon", onto the surface of the sensor, with subsequent cross-linking of the layer;
(c) extracting any toxic components from the coated sensor (e.g. using 1:1 mixture of methanol:water overnight at 40°C), followed by autoclaving;
(d) removing the sensor from the slide and cutting from it a disc of about 4mm diameter; and (e) inserting a disc into a contact lens mould containing a contact lens and PVA, preferably Nelfilcon, then cross-I inking and autoclaving the components to form the finished lens.
A holographic sensor of the type used in the invention generally comprises a medium and, disposed throughout the volume of the medium, a hologram. The support medium may interact with an analyte resulting in a variation of a physical property of the medium. This variation induces a change in an optical characteristic of the holographic element, such as its polarisability, reflectance, refractance or absorbance. If any change occurs whilst the hologram is being replayed by incident broad band, non-ionising electromagnetic radiation, then a colour or intensity change, for example, may be observed.
The sensor may be prepared according to the methods disclosed in WO
A-95/26499, WO-A-99/63408 and WO-A-03/087789. The contents of these specifications are incorporated herein by reference.
More than one hologram may be supported on, or in, a holographic element. Means may be provided to detect the or each variation in radiation emanating from the or each hologram, arising as a result of a variation in the or each optical characteristic. The holographic elements may be dimensioned and arranged so as to sense two independent events/species and to affect, simultaneously, or otherwise, radiation in two different ways. Holographic elements may be provided in the form of an array.
An illuminating source of non-ionising radiation, for example visible light, may be used to observe variations) in the, or each, optical characteristic of the holographic element. The extent of interaction between the holographic medium and the analyte species is reflected in the degree of change of the physical property, which is detected as a variation in an optical characteristic, preferably a shift in wavelength of non-ionising radiation.
The property of the holographic element which varies may be its charge density, volume, shape, density, viscosity, strength, hardness, charge, hydrophobicity, swellability, integrity, cross-link density or any other physical property. Variation of the or each physical property, in turn, causes a variation of an optical characteristic, such as the polarisability, reflectance, refractance or absorbance of the holographic element.
There are a number of basic ways to change a physical property, and thus vary an optical characteristic. The physical property that varies is preferably the volume of the support medium and, in turn, the spacing of the holographic fringes of the holographic element. This variation may be achieved by incorporating specific groups into the support matrix, where these groups undergo a change in, for example, conformation, charge or the degree of cross-linking upon interaction with the analyte, and cause an expansion or contraction of the support medium. An example of such a group is the specific binding conjugate of an analyte species. Another variation is in th a active water, solvent or charge content of the support medium. In this case, the holographic support medium is preferably in the form of a gel.
Analyte molecules that can react with at least two functional groups in the element may form a reversible cross-link between separate parts of the support matrix, thereby altering the visco-elastic properties of the support matrix.
Consequently, if present within a solvent-containing environment, and the support matrix changes, the support matrix contracts and the separation of the fringes is reduced. Specificity may be provided by ensuring that specific binding sites are provided within the medium.
The support medium may comprise a receptor which is capable of binding or interacting specificallywith the analyte. Suitable receptors include antibodies, lectins, hormone receptors, drug receptors, enzymes, aptamers, nucleic acids, nucleic acid analogues, and fragments thereof.
A receptor may be incorporated into a support med ium using any suitable method known in the art. For example, a prepolymer and receptor may comprise matching functional groups; the two components can then be covalently linked with one another. Alternatively, a receptor may be incorporated in a vinylic monomer which a component of the lens-forming material.
One parameter determining the response of the system is the extent of cross-linking. The number of cross-linking points due to polymerisation of monomers should not be so great that complex formation between polymer and analyte-binding groups is relatively low, since the polymer film may become too rigid. This may inhibit the swelling of the support medium.
By way of example of a glucose sensor, a hydroge 1-based hologram may have a support medium comprising pendant glucose groups and a lectin, preferably concanavalin A (con A). The lectin binds to the pendant glucose groups and acts as a cross-linker in the polymer structure. In the presence of freely diffusible glucose, the extent of cross-linking will decrease as glucose in solution displaces polymer-attached glucose from the binding sites on the lectin, resulting in swelling of the polymer. Volume changes in hydrogel films containing pendant glucose groups and con A can be observed using a reflection hologram.
Field of the Invention This invention relates to an ophthalmic device comprising a holographic sensor.
Background to the Invention Ophthalmic devices, for example contact lenses, comprising holographic elements are known. Typically, a holographic element is used to focus incoming light. The holographic element may have a programmed activating angle providing two or more optical powers. The use of a holographic element allows the user to see clear and unimpaired images, thereby overcoming many of the shortfalls of traditional simultaneous vision and translating lenses.
Holographic optical inserts are described, for example, in WO-A-99/34239, WO-A-99/34244, WO-A-02/054137 and WO-A-99/34248.
The need for minimally invasive, easy-to-use glucose sensors has motivated the investigation of numerous approaches. One particular area of interest is ophthalmic glucose sensors, i.e. those for the detection of glucose in the eye. The levels of glucose in the eye are known to correlate with those in the blood, and thus blood levels of glucose can be monitored indirectly by measuring the levels in an ocular fluid such as tears.
US-A-200310027240 describes an ocular insert for the detection of glucose. The insert comprises a polymerised crystalline colloidal array (PCCA) which is polymerised in a hydrogel, and a molecular recognition component capable of responding to glucose. The array has a lattice spacing that changes when the volume of the hydrogel changes, causing the diffracted wavelength of the array to change.
WO-A-95/26499 discloses a holographic sensor, based on a volume hologram. This sensor comprises an analyte-sensitive matrix having an optical transducing structure disposed throughout its volume. Because of this physical arrangement of the transducer, the optical signal generated by the sensor is very sensitive to volume changes or structural rearrangements taking place in the analyte-sensitive matrix as a result of interaction or reaction with the analyte.
For example, a sensor comprising a gelatin-based holographic medium may be used to detect trypsin. Trypsin acts on the gelatin medium, irreversibly destroying the integrity of the holographic support medium. Holographic sensors may also be used to detect changes in, for example, pH.
Although sensors of the kind described in US-A-2003/0027240 may be used to detect levels of glucose in the eye, there remains the need for ophthalmic sensors which allowfor accurate, real-tim a detection of analytes such as glucose.
Summary of the Invention The present invention is based on the realisati on that holographic sensing technology, when incorporated into a contact lens or other ophthalmic device, provides an accurate yet minimally invasive method of detection of an ocular analyte. Such sensing technology may allow for the continuous, real-time sensing of glucose or other carbohydrates. The invention thus may improve the lives of patients having diabetes and decrease such patients' risk of developing hypoglycemia or hyperglycemia.
Afirst aspect of the invention is an ophthalmic device which comprises a holographic element comprising a medium and, dis posed therein, a hologram, wherein an optical characteristic of the element changes as a result of a variation of a physical property of the medium, and wherein the variation arises as a result of interaction between the medium and an analyte present in an ocular fluid. The device may be a contact lens or an ocular implant.
Another aspect of the invention is a method of detection of an analyte in an ocular fluid, the method comprising detecting any change of the optical characteristic of the holographic element of a device of the invention with the fluid, in the eye.
Another aspect of the invention is a method for the production of a device of the invention which comprises contacting the holographic element with a contact lens, wherein the contacted regions of the element and the lens are cross-linkable; and cross-linking said regions. Preferably, at least one of the contacted regions comprises PVA, more preferably Nelfilcon.
The invention may be used for the detection of ocular analytes such as glucose or lactate. The interaction is preferably reversible so that both the interaction and reverse interaction can occur, allowing the analyte to be continuously detected, preferably in real time. The interaction is preferably a chemical reaction.
Description of the Invention The term "glucose" as used herein refers to the known cyclic and linear forms of glucose.
w The term "ophthalmic device" as used herein refers to contact lenses (both hard and soft), corneal onlays, implantable ophthalmic devices and the like.
The term "contact lens" as used herein refers to any hard or soft lens used on the eye or ocular vicinity for vision correction, diagnosis, sample collection, drug delivery, wound healing, cosmetic appearance or other ophthalmic application. The lens may be a daily-disposable, daily-wear or extended-wear lens.
The term "implantable ophthalmic device" as used herein refers to an ophthalmic device which is used in, on or about the eye or ocular vicinity.
Such devices include intraocular lenses, subconjunctival lenses, intracorneal lenses, and shunts/implants (e.g. a stent or glaucoma shunt) that can rest in the cul de sac of an eye.
In a preferred embodiment, the insert is in the form of a contact lens. The lens may be manufactured using any suitable material known in the art. The lens material may be formed by the polymerisation of one or more monomers and optionally one or more prepolymers. The material may comprise a photoinitiator, visibility tinting agent, UV-blocking agent and/or a photosensitiser.
A preferred group of lens materials are prepolymers which are water-soluble and/or meltable. It is preferred that the material comprises one or more prepolymers which are in a substantially pure form (e.g. purified by ultrafiltration). Preferred prepolymers include water-soluble crosslinkable polyvinyl alcohol) prepolymers (as described in US5583163 and US6303687);
a water-soluble vinyl group-terminated polyurethane, obtainable by reacting an isocyanate-capped polyurethane with an ethylenically unsaturated amine (primary or secondary amine) or an ethylenically unsaturated monohydroxy compound, wherein the isocyanate-capped polyurethane can be a copolymerisation product of at least one polyalkylene glycol, a compound containing at least 2 hydroxyl groups, and at least one compound with two or more isocyanate groups; derivatives of a polyvinyl alcohol, polyethyleneimine or polyvinylamine (see, for example, US5849841); a water-soluble crosslinkable polyurea prepolymer as described in US6479587; crosslinkable polyacrylamide;
crosslinkable statistical copolymers of vinyl lactam, MMA and a comonomer, as disclosed in EP-A-0655470 and US5712356; crosslinkable copolymers of vinyl lactam, vinyl acetate and vinyl alcohol, as disclosed in EP-A-0712867 and US5665840; polyether-polyester copolymers with crosslinkable side chains, as disclosed in EP-A-0932635; branched polyalkylene glycol-urethane prepolymers, as disclosed in EP-A-0958315 and US6165408; polyalkylene glycol tetra(meth)acrylate prepolymers, as disclosed in EP-A-0961941 and US6221303; and crosslinkable polyallylamine gluconolactone prepolymers, as disclosed in WO-A-00/31150.
The lens may comprise a hydrogel material. Typically, hydrogel materials are polymeric materials which are capable of absorbing at least 10% by weight of water when fully hydrated. Hydrogel materials include polyvinyl alcohol) (PVA), modified PVA (e.g. nelfilcon A), poly(hydroxyethyl methacrylate), polyvinyl pyrrolidone), PVA with a poly(carboxylic acid) (e.g. carbopol), polyethylene glycol), polyacrylamide, polymethacrylamide, silicone-containing hydrogels, polyurethane, polyurea, and the like.
Alternatively, the device may be an implantable ophthalmic device.
Glucose levels in tears may be much lower than blood glucose levels. With an implantable ophthalmic sensor, one can monitor glucose levels in aqueous humor or interstitial fluid, where glucose levels can be much higher than glucose levels in tears. Preferably, the device is in the form of a subconjunctive implant, intracorneal lens, stent or glaucoma shunt.
The holographic support medium is one in which a hologram can be made and which is capable of exhibiting one or more of the properties of the sensitive mechanisms described herein. The hologram may be disposed on or in, part of or throughout the bulk of the volume of the support medium. Particularly in the case of a contact lens, the support medium may be an integral part of the device, e.g. the body of a lens may itself comprise or form a holographic support medium.
The support medium preferably comprises a native or modified matrix with 5 viscoelastic properties which alter as a result of an interaction with an analyte species. For example, the matrix may be formed from the copolymerisation of (meth)acrylamide and/or (meth)acrylate-derived comonomers. In particular, the monomer HEMA (hydroxyethyl methacrylate) is readily polymerisable and cross-linkable. PoIyHEMA is a versatile support material since it is swellable, hydrophilic and widely biocompatible.
A device in the form of a contact lens is preferably obtained by forming a holographic element and then embedding the element into a contact lens. For example, a contact lens sensor may be obtained using the following protocol:
(a) forming a polymeric holographic sensor(e.g. using phenylboronate ligands) on a glass slide or similar surface;
(b) coating a layer of polyvinylalcohol (PVA), preferably "Nelfilcon", onto the surface of the sensor, with subsequent cross-linking of the layer;
(c) extracting any toxic components from the coated sensor (e.g. using 1:1 mixture of methanol:water overnight at 40°C), followed by autoclaving;
(d) removing the sensor from the slide and cutting from it a disc of about 4mm diameter; and (e) inserting a disc into a contact lens mould containing a contact lens and PVA, preferably Nelfilcon, then cross-I inking and autoclaving the components to form the finished lens.
A holographic sensor of the type used in the invention generally comprises a medium and, disposed throughout the volume of the medium, a hologram. The support medium may interact with an analyte resulting in a variation of a physical property of the medium. This variation induces a change in an optical characteristic of the holographic element, such as its polarisability, reflectance, refractance or absorbance. If any change occurs whilst the hologram is being replayed by incident broad band, non-ionising electromagnetic radiation, then a colour or intensity change, for example, may be observed.
The sensor may be prepared according to the methods disclosed in WO
A-95/26499, WO-A-99/63408 and WO-A-03/087789. The contents of these specifications are incorporated herein by reference.
More than one hologram may be supported on, or in, a holographic element. Means may be provided to detect the or each variation in radiation emanating from the or each hologram, arising as a result of a variation in the or each optical characteristic. The holographic elements may be dimensioned and arranged so as to sense two independent events/species and to affect, simultaneously, or otherwise, radiation in two different ways. Holographic elements may be provided in the form of an array.
An illuminating source of non-ionising radiation, for example visible light, may be used to observe variations) in the, or each, optical characteristic of the holographic element. The extent of interaction between the holographic medium and the analyte species is reflected in the degree of change of the physical property, which is detected as a variation in an optical characteristic, preferably a shift in wavelength of non-ionising radiation.
The property of the holographic element which varies may be its charge density, volume, shape, density, viscosity, strength, hardness, charge, hydrophobicity, swellability, integrity, cross-link density or any other physical property. Variation of the or each physical property, in turn, causes a variation of an optical characteristic, such as the polarisability, reflectance, refractance or absorbance of the holographic element.
There are a number of basic ways to change a physical property, and thus vary an optical characteristic. The physical property that varies is preferably the volume of the support medium and, in turn, the spacing of the holographic fringes of the holographic element. This variation may be achieved by incorporating specific groups into the support matrix, where these groups undergo a change in, for example, conformation, charge or the degree of cross-linking upon interaction with the analyte, and cause an expansion or contraction of the support medium. An example of such a group is the specific binding conjugate of an analyte species. Another variation is in th a active water, solvent or charge content of the support medium. In this case, the holographic support medium is preferably in the form of a gel.
Analyte molecules that can react with at least two functional groups in the element may form a reversible cross-link between separate parts of the support matrix, thereby altering the visco-elastic properties of the support matrix.
Consequently, if present within a solvent-containing environment, and the support matrix changes, the support matrix contracts and the separation of the fringes is reduced. Specificity may be provided by ensuring that specific binding sites are provided within the medium.
The support medium may comprise a receptor which is capable of binding or interacting specificallywith the analyte. Suitable receptors include antibodies, lectins, hormone receptors, drug receptors, enzymes, aptamers, nucleic acids, nucleic acid analogues, and fragments thereof.
A receptor may be incorporated into a support med ium using any suitable method known in the art. For example, a prepolymer and receptor may comprise matching functional groups; the two components can then be covalently linked with one another. Alternatively, a receptor may be incorporated in a vinylic monomer which a component of the lens-forming material.
One parameter determining the response of the system is the extent of cross-linking. The number of cross-linking points due to polymerisation of monomers should not be so great that complex formation between polymer and analyte-binding groups is relatively low, since the polymer film may become too rigid. This may inhibit the swelling of the support medium.
By way of example of a glucose sensor, a hydroge 1-based hologram may have a support medium comprising pendant glucose groups and a lectin, preferably concanavalin A (con A). The lectin binds to the pendant glucose groups and acts as a cross-linker in the polymer structure. In the presence of freely diffusible glucose, the extent of cross-linking will decrease as glucose in solution displaces polymer-attached glucose from the binding sites on the lectin, resulting in swelling of the polymer. Volume changes in hydrogel films containing pendant glucose groups and con A can be observed using a reflection hologram.
A volume change in the hydrogel alters the fringe separation of the holographic structure and can be followed as a shift in the peak wavelength of the spectral reflected response.
Water-based systems are preferred in such a holographic sensor, since they protect the lectin from exposure to organic solvents. Examples of suitable glucose components are high molecular weight dextran, and the monomers allylglucoside and 2-glucosyloxyethyl methacrylate (GEMA). Dextran, having no inherent polymerisable functionality, can be entrapped during the polymerisation of acrylamide-based monomers; allylglucoside and GEMA can be polymerised either individually or together with comonomers. The polymers are preferably prepared as thin films on glass supports.
A holographic glucose sensor may comprise any suitable glucose receptor, particularly one which allows a reversible change in a physical property of the support medium upon binding with glucose. For example, the support medium may comprise pendant boronic acid groups, such as phenylboronic acid or a derivative thereof. Two adjacent diol groups in glucose bind with a boronic acid group in a reversible condensation reaction. Thus in a holographic element, reaction of glucose with pendant phenylboronic acid groups causes an expansion of the support medium, due to the formation of boronate esters.
Without wishing to be bound by theory, it is believed that the boronate esters are negatively charged and effect a Donan potential, causing water to partition into the support medium. This expansion is observed as a shift in the reflectance maxima to longer wavelengths. The sensing ability of boronic acid groups is strongly dependent on the molecular geometry and the aromatic species where the boronic acid group is present. Thus, glucose sensitive probes can be made with a variety of affinities, in the mM range for blood glucose, and in the pM
range for tear glucose. Preferred boronic acid groups include those described in WO-A-04/081624.
Boronic acid compounds, in particular phenylboronicacid compounds, are versatile receptors since they may be used for the detection of a variety of carbohydrates. In physiological fluids, this lack of selectivity is not a problem because most sugars are found on glycoproteins and other macromolecular structures, i.e. they are already bound and thus cannot bind to the boronic groups of the support medium. Glucose is the only sugar that is found free in relatively high concentration. Lactate (lactic acid), however, may pose a problem since it is an a-hydroxy acid which binds to boronic acid groups and is, in ocular fluids, generally present in a greater concentration than glucose.
The problem of lactate interference can be addressed by incorporating, in the device, a group which repels lactate. Lactate carries an overall negative charge in physiological fluids and thus, for example, the support medium may carry a group having a negative charge, the magnitude of which will be apparent to those skilled in the art. An example of such a group is glycolic acid, which can be incorporated into the support medium by the polymerisation of monomers including, for example, acrylamidoglycolic acid. The glycolic acid moiety competes with glucose and lactate for available phenylboronic acid sites however, since the moiety carries a negative charge, it repels lactate but not glucose. Alternatively, the boronic receptor may itself carry a substantial negative charge or polarisation, e.g. by coordinating the boron atom with suitable electron-donating groups. An example of such a boronic acid is 5-fluoro-2-methylacrylamidophenylboronic acid. Another option is to attach negatively charged groups to the phenyl group of a phenylboronate receptor. The surface of the holographic element or the device may be negatively charged, to reduce the effects of lactate interference.
A sensor can also be made more selective for glucose by incorporating pendant amine groups in the support medium. The nitrogen atom of the amine group may form an intramolecular bond with the boron atom, thereby promoting formation of the more reactive tetrahedral conformation about the boron atom.
The support medium may comprise one or more macrocyclic groups such as crown ethers, which reversibly bind a range of ionic species. Crown ethers are well known to reversibly bind Group I and Group II metal ions. Therefore a crown ether which is specific to an ionic analyte can be immobilised in the support medium and used to continuously monitor the presence of the analyte.
The following Examples illustrate the invention.
Example 1 A contact lens was produced according to the protocol described above.
The embedded holographic element comprised 12% mol of 3-acrylamidophenylboronic acid, the synthesis of which is described in WO-A-04/081624.
5 The lens was placed into the eye of a human volunteer, who then ingested a 44g bolus of glucose. The response of the contact lens sensor was measured in terms of the shift in the wavelength of reflection. Blood glucose levels were also monitored directly using a conventional glucose sensor.
Fig. 1 shows the response of the contact lens sensor, Fig. 2 that of the 10 blood glucose sensor. It is evident that the responses of the two sensors are similar, the peak level of glucose being absorbed at around t = 25 minutes.
Example 2 An experiment similar to that of Example 1 was performed, using an ophthalmic implant comprising the sensor. The support medium was coated with Nelfilcon (Cibavision).
The experiment was conducted on a rabbit, instead of a human volunteer, the device implanted subcutaneously just below the eye. The rabbit was then anaesthetised using an xylazine-based protocol which causes blood levels of glucose to rise to a level commonly seen in diabetic patients (see Cameron et al, Diabetes Technology & Therapeutics, 2001, 3, 2O1-207). The concentration of glucose was then monitored using the implant. Again, blood levels of glucose were also monitored directly.
Fig. 3 shows the response of the holographic implant, Fig. 4 that of the blood glucose sensor. As in Example 1, the responses of the two sensors are similar.
Example 3 A holographic support medium was formed by copolymerising 13 mol%
5-fluoro-2-methylacrylamidophenylboronic acid (the synthesised according to WO-A-04/081624) and 3% MBA in acrylamide. A holographic image was then recorded in the resulting medium and the sensor used to detect glucose in PBS
at pH 7.4 and a temperature of 30°C. A similar experiment was performed to test the sensor's response to lactate.
Water-based systems are preferred in such a holographic sensor, since they protect the lectin from exposure to organic solvents. Examples of suitable glucose components are high molecular weight dextran, and the monomers allylglucoside and 2-glucosyloxyethyl methacrylate (GEMA). Dextran, having no inherent polymerisable functionality, can be entrapped during the polymerisation of acrylamide-based monomers; allylglucoside and GEMA can be polymerised either individually or together with comonomers. The polymers are preferably prepared as thin films on glass supports.
A holographic glucose sensor may comprise any suitable glucose receptor, particularly one which allows a reversible change in a physical property of the support medium upon binding with glucose. For example, the support medium may comprise pendant boronic acid groups, such as phenylboronic acid or a derivative thereof. Two adjacent diol groups in glucose bind with a boronic acid group in a reversible condensation reaction. Thus in a holographic element, reaction of glucose with pendant phenylboronic acid groups causes an expansion of the support medium, due to the formation of boronate esters.
Without wishing to be bound by theory, it is believed that the boronate esters are negatively charged and effect a Donan potential, causing water to partition into the support medium. This expansion is observed as a shift in the reflectance maxima to longer wavelengths. The sensing ability of boronic acid groups is strongly dependent on the molecular geometry and the aromatic species where the boronic acid group is present. Thus, glucose sensitive probes can be made with a variety of affinities, in the mM range for blood glucose, and in the pM
range for tear glucose. Preferred boronic acid groups include those described in WO-A-04/081624.
Boronic acid compounds, in particular phenylboronicacid compounds, are versatile receptors since they may be used for the detection of a variety of carbohydrates. In physiological fluids, this lack of selectivity is not a problem because most sugars are found on glycoproteins and other macromolecular structures, i.e. they are already bound and thus cannot bind to the boronic groups of the support medium. Glucose is the only sugar that is found free in relatively high concentration. Lactate (lactic acid), however, may pose a problem since it is an a-hydroxy acid which binds to boronic acid groups and is, in ocular fluids, generally present in a greater concentration than glucose.
The problem of lactate interference can be addressed by incorporating, in the device, a group which repels lactate. Lactate carries an overall negative charge in physiological fluids and thus, for example, the support medium may carry a group having a negative charge, the magnitude of which will be apparent to those skilled in the art. An example of such a group is glycolic acid, which can be incorporated into the support medium by the polymerisation of monomers including, for example, acrylamidoglycolic acid. The glycolic acid moiety competes with glucose and lactate for available phenylboronic acid sites however, since the moiety carries a negative charge, it repels lactate but not glucose. Alternatively, the boronic receptor may itself carry a substantial negative charge or polarisation, e.g. by coordinating the boron atom with suitable electron-donating groups. An example of such a boronic acid is 5-fluoro-2-methylacrylamidophenylboronic acid. Another option is to attach negatively charged groups to the phenyl group of a phenylboronate receptor. The surface of the holographic element or the device may be negatively charged, to reduce the effects of lactate interference.
A sensor can also be made more selective for glucose by incorporating pendant amine groups in the support medium. The nitrogen atom of the amine group may form an intramolecular bond with the boron atom, thereby promoting formation of the more reactive tetrahedral conformation about the boron atom.
The support medium may comprise one or more macrocyclic groups such as crown ethers, which reversibly bind a range of ionic species. Crown ethers are well known to reversibly bind Group I and Group II metal ions. Therefore a crown ether which is specific to an ionic analyte can be immobilised in the support medium and used to continuously monitor the presence of the analyte.
The following Examples illustrate the invention.
Example 1 A contact lens was produced according to the protocol described above.
The embedded holographic element comprised 12% mol of 3-acrylamidophenylboronic acid, the synthesis of which is described in WO-A-04/081624.
5 The lens was placed into the eye of a human volunteer, who then ingested a 44g bolus of glucose. The response of the contact lens sensor was measured in terms of the shift in the wavelength of reflection. Blood glucose levels were also monitored directly using a conventional glucose sensor.
Fig. 1 shows the response of the contact lens sensor, Fig. 2 that of the 10 blood glucose sensor. It is evident that the responses of the two sensors are similar, the peak level of glucose being absorbed at around t = 25 minutes.
Example 2 An experiment similar to that of Example 1 was performed, using an ophthalmic implant comprising the sensor. The support medium was coated with Nelfilcon (Cibavision).
The experiment was conducted on a rabbit, instead of a human volunteer, the device implanted subcutaneously just below the eye. The rabbit was then anaesthetised using an xylazine-based protocol which causes blood levels of glucose to rise to a level commonly seen in diabetic patients (see Cameron et al, Diabetes Technology & Therapeutics, 2001, 3, 2O1-207). The concentration of glucose was then monitored using the implant. Again, blood levels of glucose were also monitored directly.
Fig. 3 shows the response of the holographic implant, Fig. 4 that of the blood glucose sensor. As in Example 1, the responses of the two sensors are similar.
Example 3 A holographic support medium was formed by copolymerising 13 mol%
5-fluoro-2-methylacrylamidophenylboronic acid (the synthesised according to WO-A-04/081624) and 3% MBA in acrylamide. A holographic image was then recorded in the resulting medium and the sensor used to detect glucose in PBS
at pH 7.4 and a temperature of 30°C. A similar experiment was performed to test the sensor's response to lactate.
The results are shown in Fig. 5. The improved selectivity to glucose over lactate is attributable to the oxygen- and nitrogen-based electron-donating groups coordinated to the boron atom of the phenylboronate receptor. These groups increase the negative change around the boron atom.
Example 4 A medium was obtained by polymerising 12 mol% 3-acrylamidophenylboronic acid, 12 mol% acrylamidoglycolic acid and 76 mol%
acrylamide, using 2% (w/v) of 2-dimethoxy-2-phenyl-acetophenone (a free radical initiator) in dimethyl sulphoxide. A hologram was recorded in the medium, and the resulting sensor tested for its response to glucose and lactate.
The results are shown in Fig. 6. The presence of acrylamidoglycolic acid reduced the response of the sensor to the two analytes, as the negative charge of the acidic moiety causes a significant degree of swelling of the polymeric medium. However, the sensor was more responsive to glucose than lactate, because the glycolic acid component carries a negative charge which repels lactate, without significantly affecting glucose binding.
Example 5 A support medium was formed by copolymerising 11.9 mol% 3 acrylamidophenylboronicacid, 9.2 mol% N-[3-(dimethylamino)propyl]acrylamide, 2.9 mol% methylenebisacrylamide and 76 mol % acrylamide, by exposure to UV
light for 1 hour. Silver ions, present in an acetic acid solution, were diffused into the medium, the acidic solution present to prevent "fogging" of the silver by the amine component. A hologram was recorded in the medium, and the resulting sensor tested for its response to glucose and lactate.
The results are shown in Fig. 7. The sensor was selective for glucose over lactate; the peak wavelength shift for lactate was only about 12% of that for glucose at the same concentration. Also, the wavelength shift is a negative shift for glucose, whereas the binding of lactate effects a positive shift. The presence of "background" (4mM) lactate had a negligible effect of the sensor's response to glucose.
Example 4 A medium was obtained by polymerising 12 mol% 3-acrylamidophenylboronic acid, 12 mol% acrylamidoglycolic acid and 76 mol%
acrylamide, using 2% (w/v) of 2-dimethoxy-2-phenyl-acetophenone (a free radical initiator) in dimethyl sulphoxide. A hologram was recorded in the medium, and the resulting sensor tested for its response to glucose and lactate.
The results are shown in Fig. 6. The presence of acrylamidoglycolic acid reduced the response of the sensor to the two analytes, as the negative charge of the acidic moiety causes a significant degree of swelling of the polymeric medium. However, the sensor was more responsive to glucose than lactate, because the glycolic acid component carries a negative charge which repels lactate, without significantly affecting glucose binding.
Example 5 A support medium was formed by copolymerising 11.9 mol% 3 acrylamidophenylboronicacid, 9.2 mol% N-[3-(dimethylamino)propyl]acrylamide, 2.9 mol% methylenebisacrylamide and 76 mol % acrylamide, by exposure to UV
light for 1 hour. Silver ions, present in an acetic acid solution, were diffused into the medium, the acidic solution present to prevent "fogging" of the silver by the amine component. A hologram was recorded in the medium, and the resulting sensor tested for its response to glucose and lactate.
The results are shown in Fig. 7. The sensor was selective for glucose over lactate; the peak wavelength shift for lactate was only about 12% of that for glucose at the same concentration. Also, the wavelength shift is a negative shift for glucose, whereas the binding of lactate effects a positive shift. The presence of "background" (4mM) lactate had a negligible effect of the sensor's response to glucose.
Claims (17)
1. An ophthalmic device which comprises a holographic element comprising a medium and, disposed therein, a hologram, wherein an optical characteristic of the element changes as a result of a variation of a physical property of the medium, and wherein the variation arises as a result of interaction between the medium and an analyte present in an ocular fluid.
2. A device according to claim 1, wherein the medium is polymeric.
3. A device according to claim 2, wherein the medium is obtainable by the polymerisation of monomers including acrylamide.
4. A device according to any preceding claim, wherein the holographic element does not contain silver.
5. A device according to any preceding claim, wherein the interaction is a chemical reaction.
6. A device according to claim 5, wherein the reaction is reversible.
7. A device according to any preceding claim, wherein the analyte is glucose.
8. A device according to claim 7, wherein the medium comprises a phenylboronic acid group.
9. A device according to claim 8, wherein the medium is obtainable by the polymerisation of monomers including 3-acrylamidophenylboronic acid or 5-fluoro-2-methacrylamidophenylboronic acid.
10. A device according to claim 8 or claim 9, wherein the medium comprises a group which is capable of repelling lactate, the group comprising a substantial negative change.
11. A device according to claim 10, wherein the boron atom of the boronic acid group carries the substantial negative change.
12. A device according to claim 10 or claim 11, wherein the medium is formed by the polymerisation of monomers including acrylamidoglycolic acid.
13. A device according to any of claims 7 to 12, wherein the medium comprises an amine group.
14. A device according to any preceding claim, which is a contact lens.
15. A device according to any of claims 1 to 13, which is implantable.
16. A method of detection of an analyte in an ocular fluid, which comprises detecting any change of the optical characteristic of the holographic element of a device according to any of claims 1 to 15 with the fluid, in the eye.
17. A method for the production of a device according to claim 14, which comprises contacting the holographic element with a contact lens, wherein the contacted regions of the element and the lens are cross-linkable; and cross-linking said regions.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0322488.8 | 2003-09-25 | ||
GB0322488A GB0322488D0 (en) | 2003-09-25 | 2003-09-25 | Ophthalmic device |
GB0401399A GB0401399D0 (en) | 2004-01-22 | 2004-01-22 | Ophthalmic device |
GB0401399.1 | 2004-01-22 | ||
PCT/GB2004/004093 WO2005031442A1 (en) | 2003-09-25 | 2004-09-27 | Ophthalmic device comprising a holographic sensor |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2540076A1 true CA2540076A1 (en) | 2005-04-07 |
Family
ID=34395443
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002540076A Abandoned CA2540076A1 (en) | 2003-09-25 | 2004-09-27 | Ophthalmic device comprising a holographic sensor |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1664909A1 (en) |
JP (1) | JP4566996B2 (en) |
AU (1) | AU2004276949B2 (en) |
CA (1) | CA2540076A1 (en) |
WO (1) | WO2005031442A1 (en) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0412654D0 (en) * | 2004-06-07 | 2004-07-07 | Univ Cambridge Tech | Method of detection |
US9248614B2 (en) | 2004-06-30 | 2016-02-02 | Novartis Ag | Method for lathing silicone hydrogel lenses |
GB0419827D0 (en) | 2004-09-07 | 2004-10-13 | Univ Cambridge Tech | Sensor |
GB0514699D0 (en) * | 2005-07-18 | 2005-08-24 | Smart Holograms Ltd | Holographic sensors and their use |
CA2618035A1 (en) | 2005-08-10 | 2007-02-15 | Novartis Ag | Silicone hydrogels |
GB0520116D0 (en) * | 2005-10-03 | 2005-11-09 | Smart Holograms Ltd | Use of holographic sensors |
GB0522796D0 (en) * | 2005-11-08 | 2005-12-14 | Smart Holograms Ltd | Novel boronate complex and its use in a glucose sensor |
US8334140B2 (en) | 2005-11-08 | 2012-12-18 | Smart Holograms Limited | Boronate complex and its use in a glucose sensor |
WO2007068453A2 (en) | 2005-12-14 | 2007-06-21 | Novartis Ag | Method for preparing silicone hydrogels |
GB0617730D0 (en) * | 2006-09-08 | 2006-10-18 | Smart Holograms Ltd | Analyte detection |
US20080151181A1 (en) * | 2006-12-20 | 2008-06-26 | Bausch & Lomb Incorporated | Coatings and Solutions for Contact Lenses |
WO2010077646A2 (en) * | 2008-12-30 | 2010-07-08 | Bausch & Lomb Incorporated | Method of applying renewable polymeric lens coating |
WO2010077709A2 (en) * | 2008-12-30 | 2010-07-08 | Bausch & Lomb Incorporated | Biomedical devices |
US8454689B2 (en) * | 2008-12-30 | 2013-06-04 | Bausch & Lomb Incorporated | Brush copolymers |
WO2011034592A1 (en) * | 2009-09-18 | 2011-03-24 | University Of Akron | Optical device and method for non-invasive real-time testing of blood sugar levels |
MY150535A (en) * | 2009-09-22 | 2014-01-30 | Coopervision Int Holding Co Lp | Wettable hydrogel materials for use in ophthalmic applications and method |
JP5622188B2 (en) * | 2010-01-05 | 2014-11-12 | 独立行政法人物質・材料研究機構 | Phenylboronic acid monomer and phenylboronic acid polymer |
JP6194127B2 (en) * | 2015-08-10 | 2017-09-06 | 株式会社メニコン | Glucose detector and glucose detection method |
WO2019031114A1 (en) * | 2017-08-10 | 2019-02-14 | Jsr株式会社 | Polymer, resin composition, resin film, method for producing patterned resin film, and electronic component |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9406142D0 (en) * | 1994-03-28 | 1994-05-18 | British Tech Group | A sensor |
US7105352B2 (en) * | 1996-11-06 | 2006-09-12 | University Of Pittsburgh | Intelligent polymerized crystalline colloidal array carbohydrate sensors |
US6139146A (en) * | 1997-12-29 | 2000-10-31 | Novartis Ag | Programmable corrective lenses |
HUP0100091A3 (en) * | 1997-12-29 | 2004-07-28 | Univ California | Composite holographic multifocal lens |
US6579673B2 (en) * | 1998-12-17 | 2003-06-17 | Kimberly-Clark Worldwide, Inc. | Patterned deposition of antibody binding protein for optical diffraction-based biosensors |
CN1196436C (en) * | 1999-08-26 | 2005-04-13 | 诺瓦提斯公司 | Ocular analyte senser |
US6366793B1 (en) * | 1999-09-10 | 2002-04-02 | Beckman Coulter, Inc. | Minimally invasive methods for measuring analtes in vivo |
GB0000209D0 (en) * | 2000-01-07 | 2000-03-01 | Holmetrica Limited | Holographic multiplexed image sensor |
-
2004
- 2004-09-27 AU AU2004276949A patent/AU2004276949B2/en not_active Ceased
- 2004-09-27 EP EP04768637A patent/EP1664909A1/en not_active Withdrawn
- 2004-09-27 JP JP2006527481A patent/JP4566996B2/en not_active Expired - Fee Related
- 2004-09-27 WO PCT/GB2004/004093 patent/WO2005031442A1/en active Application Filing
- 2004-09-27 CA CA002540076A patent/CA2540076A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1664909A1 (en) | 2006-06-07 |
JP4566996B2 (en) | 2010-10-20 |
JP2007506999A (en) | 2007-03-22 |
AU2004276949B2 (en) | 2008-07-31 |
WO2005031442A1 (en) | 2005-04-07 |
AU2004276949A1 (en) | 2005-04-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8241574B2 (en) | Ophthalmic device comprising a holographic sensor | |
AU2004276949B2 (en) | Ophthalmic device comprising a holographic sensor | |
US7402441B2 (en) | Method of detecting an analyte in a fluid | |
AU2008252936B2 (en) | Hydrogel implant for sensing metabolites in body tissue | |
US7927519B2 (en) | Reflection hologram sensor in contact lens | |
AU2005252845B2 (en) | Method of detecting an analyte using a holographic sensor | |
EP1654543B1 (en) | Ophthalmic sensor | |
US5898004A (en) | Polymerized crystalline colloidal array sensors | |
Domschke et al. | Initial clinical testing of a holographic non-invasive contact lens glucose sensor | |
CA2283565A1 (en) | Novel polymerized crystalline colloidal array sensors | |
Elsherif et al. | Wearable bifocal contact lens for continual glucose monitoring integrated with smartphone readers | |
EP1949083A1 (en) | Novel boronate complex and its use in a glucose sensor | |
JP4911641B2 (en) | Holographic sensor with polymer matrix | |
Harvey et al. | Fibre optics sensors in tear electrolyte analysis: Towards a novel point of care potassium sensor | |
WO2006008524A1 (en) | Holographic sensor having heterogeneous properties | |
WO2003096876A2 (en) | Continuously operational diagnostic device | |
Domschke et al. | Holographic sensors in contact lenses for minimally-invasive glucose measurements | |
Domschke | Ophthalmic Glucose Nanosensors for Diabetes Management |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Dead |